 SAN FRANCISCO, Feb. 19, 2021 GLOBE NEWSWIRE -- BridgeBio Pharma, Inc. Nasdaq: BBIO, a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, and affiliate ML Bio Solutions today announced that the first patient has been dosed in a Phase 2 trial of BBP-418 in patients with LGMD2i. BridgeBio and ML Bios BBP-418 is the first-ever oral disease-modifying investigational treatment for LGMD2i. BBP-418 was granted Orphan Drug Designation for LGMD2i by the US Food and Drug Administration FDA in 2019, and for LGMD by the European Medicines Agency EMA in 2020. 